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 Graves’ ophthalmopathy is a potentially disfiguring, sight-threatening and 
frequent complication of Graves’ disease.  There is currently no option of preventive 
treatment and management consists mainly of amelioration of inflammatory 
processes which are usually well underway once clinical presentations become overt.  
Lymphocytic infiltration of muscular and connective tissues of the retroorbital space 
is a histological hallmark of Graves’ ophthalmopathy. The pathogenesis of Graves’ 
ophthalmopathy and whether it is the result of a Th1 or Th2 regulation remains 
controversial.  Study of inflammatory processes and cytokine profiling in human 
tissue samples were limited by sample, genetic and technique heterogeneity.  
Therefore, it is the aim of this study, to investigate the spectrum of T-lymphocyte 
cytokines expressed in tissues (spleen, thyroid & orbit) of genetically immunized 
inbred Balb/c and outbred Swiss mice by means of Real-Time PCR.  These 2 mouse 
strains were injected with plasmid encoding the thyrotropin receptor gene.  The 
results showed genetic immunization worked better in Swiss outbred than Balb/c. It 
produced significantly higher numbers of mice positive for thyrotropin receptor 
autoantibody (TRAB) detection by Flow Cytometry (FACS) and Indirect competitive 
(TBII) assays in Swiss outbred compared to Balb/c.  The titers of these 2 assays were 
also significantly higher in outbred than in inbred mice. γIFN was found to be more 
abundant in the thyroids of thyrotropin receptor vaccinated Balb/c mice than those of 
controls.  There was a dominance of γIFN and IL2 to IL5 in the ratio calculation of 
the thyroidal cytokines.  Thyroid-stimulation blocking antibody (TSBAB) also had a 
linear relationship with the expression of Th1 cytokines i.e. γIFN in the spleens and 
 xiii
orbits and IL2 in the orbits of Balb/c mice.  Expression of Th2 cytokine IL5 was 
higher in Swiss outbred mice injected with thyrotropin receptor compared to controls 
in the splenic and thyroidal tissues.  There was also a drop in expression of IL2 (Th1) 
cytokine in the vaccinated thyroid relative to control, which differ significantly from 
that in Balb/c mice.  There was also a large dominance of IL5 to IL2 or γIFN 
expression in the ratio calculation and this contrast sharply with the findings in Balb/c 
mice.  The cytokine profile evaluation in the orbital tissues showed down regulation 
of IL5 in Balb/c and γIFN, IL4 and IL5 in Swiss outbred mice.  This would imply a 
relatively quiescent immunological environment in this tissue compartment and thus 
dominance of either Th1 or Th2 response cannot be determined with confidence.  In 
this study, genetic immunization of Balb/c tended towards a Th1 bias while Swiss 
outbred mice tended towards a Th2 bias upon genetic immunization with the human 
TSHR.  The 2 mouse strains were identical in the treatment, housing and 
maintenance.  The only variance is the genetic makeup of outbred and inbred mice.  
Given the stronger antibody response in the Swiss outbred mice, it is possible that the 
genetic diversity in outbred mice contribute to a more plausible model for human 
Graves’ disease. 
 xiv
I.   INTRODUCTION 
 
 The thyroid gland is a butterfly shaped organ located immediately below the 
larynx anterior to the trachea.  It secretes two important hormones, thyroxine (T4) and 
triiodothyronine (T3).  These hormones cause an increase in nuclear transcription of 
large numbers of genes in virtually all cells of the body with resultant effect of large 
increases in protein enzymes, structural proteins, transport proteins, and other 
substances.  The outcome of all these changes is a generalized increased in functional 
activity throughout the body and a rise in the metabolic rate.  Under normal 
physiological condition, production of these two hormones from the thyroid gland is 
tightly regulated by thyrotropin (TSH) from the pituitary gland via a negative 
feedback loop by the secreted thyroid hormone.  The hypothalamus also exerts 
influence on the pituitary gland via the secretion of thyrotropin releasing hormone 
(TRH) (Figure 1). 
 
Figure 1.   An illustration of the 
physiologic control of thyroid 
function.  
In response to thyrotropin-releasing 
hormone (TRH), the pituitary gland 
secretes thyrotropin (TSH) which 
stimulates iodine trapping and 
increasing cAMP, thus thyroid 
hormone synthesis, and release of 
T3 and T4 by the thyroid gland.  
TSH is regulated by feedback from 











1.   Graves’ Disease (GD) 
 
 Thyrotoxicosis is a clinical syndrome resulting from high levels of circulating 
thyroid hormones which increases the body’s basal metabolic rate 60 - 100 per cent 
above the normal.  This is often due to excessive thyroid secretion.  Common 
manifestations include palpitation – sinus tachycardia or atrial fibrillation, agitation 
and tremor, generalized muscle weakness, proximal myopathy, angina and heart 
failure, fatigue, hyperkinesias, diarrhea, excessive sweating, intolerance to heat, 
oligomenorrhea and subfertility.  There is often weight loss despite normal appetite. 
 By far, Graves’ disease (GD) is the most common form of thyrotoxicosis and 
may occur at any age, with a peak incidence in the 20- to 40-year age group with a 
predisposition toward the female sex.  Graves’ disease is characterized by a 
generalized increase in thyroid gland volume, termed goiter.  In most patients, the 
entire thyroid gland can be increased up to 2 - 3 times above normal.  Other hallmark 
features of the disease include thyroid eye disease termed Graves’ ophthalmopathy 
(GO), and thyroid dermopathy termed pretibial myxedema.  GO is the more common 
extra-thyroidal manifestation of GD and is clinically evident in 25 - 50 percent of the 
patients.  The onset of GO may precede, coincide with, or follow the thyrotoxicosis.  
It is characterized by proptosis, periorbital and conjunctival edema, extraocular 
muscle dysfunction, and rarely, corneal ulceration or optic neuropathy.  It can be a 
disfiguring and potentially sight-threatening autoimmune disorder.  Thyroid 
dermopathy, as seen in pretibial myxedema, is a painless thickening of the skin, 
particularly over the lower tibia.  It is due to the accumulation of glycosaminoglycans 
(GAG) and is a relatively rare occurrence in GD (2 - 3%). 
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GD is an autoimmune disease characterized by the presence of autoantibodies 
directed against the thyrotropin receptor (TSHR).  These anti-TSHR autoantibodies 
(TRAB) mimic the action of TSH and activate the TSHR independent of its natural 
ligand.  Receptor activation increases the downstream signal transduction with an 
increase in cyclic AMP (cAMP) production.  There is growth and proliferation of 
thyrocytes and thyroid hormone T3 and T4 overproduction, leading to diffuse goiter 
and thyrotoxicosis.  These TRAB with stimulatory activity are known as thyroid 
stimulating antibodies (TSAB) and is of IgG subtype. 
 
1.1.   Diagnosis of Graves’ Disease 
Clinical diagnosis is made based on the triad of goiter, GO and pretibial 
myxedema if present and confirmed through biochemistry by a combination of 
suppressed TSH and elevated free T4.  In early and recurrent Graves’ disease, T3 may 
be secreted in excess before T4 is elevated.  Therefore, if TSH is suppressed and free 
T4 is not raised, serum T3 should be measured.  GD patients have autoantibodies 
against several thyroid antigens including thyroglobulin (Tg), thyroid peroxidase 
(TPO) and TSHR [8, 9].  Among these, TRAB is the pathogenic autoantibody and 
most critical in disease development.  Testing of this autoantibody is useful in the 
diagnoses of ‘apathetic’ hyperthyroid patient or patient who presents with unilateral 
exophthalmos without obvious clinical features or laboratory manifestations of GD. 
 
1.2.   The Antigen in Graves’ Disease: Thyrotropin Receptor (TSHR) 
 The TSHR is the primary antigen in GD.  It is the target of both antigen-
specific T cells and B-cell derived antibodies.  The binding of its cognate ligand TSH 
or/and pathogenic TRAB changes the receptor and brings about the signal 
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transduction across the thyroid cell membrane.  The TSHR has long been known to 
signal via cAMP signal transduction pathway.  The receptor’s cAMP signal 
transduction is regulated by TSH in a normal person.  Growth and function of the 
thyroid are stimulated by cAMP which indirectly regulates the expression of the Tg 
and TPO genes.  In Graves’ disease, TSAB mimicking the action of TSH presents a 
continued stimulation of the cAMP pathway, thus causing hyperthyroidism (Figure 
2).  Conversely, inhibition of this cascade by autoantibodies such as thyroid-
stimulation blocking antibodies (TSBAB) and thyrotropin binding inhibitor 
immunoglobulin (TBII) that block the TSHR would result in hypothyroidism. 





TSH / TRAB 
TSH 
Figure 2.  Activation of adenylyl cyclase following binding of TSH to TSHR.   
(i) Following ligand binding to the receptor, a conformational change is induced 
in the receptor to catalyze a replacement of GDP by GTP on Gα.   
(ii) The Gα-GTP complex dissociates from Gγβ and binds to adenylyl cyclase, 
stimulating cAMP synthesis.   
(iii) Bound GTP is slowly hydrolyzed to GDP by GTPase activity of Gα.   
(iv) Gα-GDP dissociates from adenylyl cyclase and reassociates with Gγβ.  Gα and 
Gγ are subunits linked to the membrane by covalent attachment to lipids [4]. 
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 The TSHR is the largest of all G protein-coupled receptors (GPCR) which 
consists of a large extracellular ligand binding domain linked to seven transmembrane 
segments, and an intracellular tail.  It is found to be much more susceptible to 
constitutive activation by mutations, deletions, or even mild trypsin digestion than 









Gain-of-function mutations are denoted by circles ( ) in the case of hyperfunctioning 
thyroid adenomas, squares ( ) in the case of familial autosomal dominant hyperthyroidism, 
diamonds ( ) in the case of sporadic congenital hyperthyroidism, and octagons ( ) in the 
case of thyroid carcinomas. Loss-of-function mutations are denoted by triangles ( ). 
Letters indicate the amino acid in the wild-type receptor. The asterisk (*) and double 
asterisk (**) indicate deletions resulting in a gain of function in hyperfunctioning thyroid 
adenomas [7]. 
 5
 The TSHR is unusual among the GPCRs in that the single-chain TSHR 
undergoes intramolecular cleavage to form ligand-binding, disulfide-linked subunits 
A (α, N-terminal extracellular portion) and B (β, membrane bound).  A segment of 
~50 residues (C-peptide region) is removed from the N-terminal end of the B subunit 
(Figure 4(i)).  This process also leads to the shedding of heavily glycosylated 
autoantibody-binding A-subunits from the cell surface which is preferentially 
recognized by TSAB (Figure 4(ii)).  The shed A-subunits have been shown to bind 
TSH even without the B-subunit.  These post-translational processes (cleavage and A-
subunit shedding) are regulated by TSH [6].  Majority of the epitopes for TSAB are 
present on the N-terminal region between amino acid residues 25 and 165 of the 
extracellular domain while those for TSBAB and TBII are on the C-terminal region 
(between amino acid residues 261 and 370) [10].  However, recent studies using 
monoclonal antibodies on TSHR epitopes indicate a much closer overlap of TSAB 
and TSBAB binding sites [11]. 
 
 
    
Figure 4.  Schematic representation of different forms of the TSHR.  
 
(i) Intramolecular cleavage of the single polypeptide chain is followed by 
removal of the C peptide region, with the A subunit remaining tethered to the 
membrane-spanning B-subunit by disulfide bonds. 








 1.3.   TSHR Autoantibodies in Graves’ Disease 
 TSHR autoantibodies (TRAB) show functional heterogeneity.  Autoantibodies 
which mimic TSH action to stimulate thyroid hormone production are called thyroid-
stimulating antibodies (TSAB), while those which block TSH actions are called 
thyroid-stimulation blocking antibodies (TSBAB).  Antibodies that inhibit TSH 
binding to the receptor are called TSH-binding inhibitor immunoglobulin (TBII) [12].  
GD patients have all three antibodies frequently coexisting in their blood (Figure 5).  
In general, TSAB should dominate over other TRAB during hyperthyroid phase of 
GD.  They can also cause transient neonatal hyperthyroidism by transplacental 
crossing of IgG from mother to fetus.  TSAB are restricted to the IgG subclass, while 




Figure 5.  A schematic representation of the relationship between 












1.4.   Detection of TRAB 
 TRAB is useful for differential diagnosis of GD from other causes of 
hyperthyroidism, for follow up of patients with GD under treatment with antithyroid 
drugs, for the diagnosis of GO and for monitoring GD in pregnancy or after delivery.  
It can be detected and measured by 3 methods: 
1. Indirect competitive assay (TBII assay), 
2. Measurement of cAMP levels stimulation in the case of TSAB, or 
measurement of suppression of TSH-mediated cAMP production in the case 
of TSBAB, 
3. Flow cytometry. 
 
1.4.1.   Indirect Competitive Assay (TBII Assay) 
 This is a competitive assay where TRAB and I125 labeled bovine TSH 
compete for the binding sites on the TSHR (Table 1).  TRAB inhibit labeled TSH 
binding to the TSHRs in a dose- and time-dependent manner.  This assay does not 










TSHr on JP26 cells 
 
TRAB in mouse serum 
Bovine TSH 
Table 1.  TSH Binding Inhibitory Immunoglobulin (TBII) Assay 
TRAB TRAB 
  
1.4.2.   TSAB and TSBAB Assays 
 Interaction of stimulating TRAB at the TSHR results in cAMP production as 
shown in Figure 2.  TSAB assay is carried out by measuring the amount of cAMP 
generated from incubation of stimulating TRAB with cells expressing TSHRs over a 
measured period of time.  TSBAB is similarly performed except that in this case, 
incubation of blocking TRAB is done in the presence of TSH and cells expressing 
TSHRs.  Since blocking TRAB inhibits TSH, a reduction of TSH-mediated cAMP 
generation is detected.  Cyclic AMP can be measured in the intra- or extra-cellular 
compartment and is usually done with a radioimmunoassay kit. 
 
1.4.3.   Detection of TRAB by Flow Cytometry 
 In this method, cells expressing TSHRs are incubated in the presence of 
TRAB-positive sera and detection is done by a secondary antibody conjugated with a 
fluorescein dye.  Cells prepared in this manner are then put through a fluorescence-
activated cell sorter (FACS) (Figure 6).  The cell stream that is passing out of the 
chamber is encased in a sheath of buffer fluid and illuminated by a laser.  Each cell is 
measured for size (forward light scatter) and granularity (90o light scatter), as well as 
for presence of colored fluorescence.  Thus by measuring the fluorescence intensity 
of each cell after interrogation by a laser beam, the machine is able to distinguish 





Figure 6. FACS, Fluorescence Activated Cell Sorter  
 
TRAB positive and TRAB negative sera can be identified based on their 

















Figure 7.  Histogram for 
TRAB bound and unbound 
population 
 
Y-axis denotes number of cells 
while X-axis showed 





2.   Graves’ Ophthalmopathy (GO) 
 
 Graves’ Ophthalmopathy is a potentially disfiguring and sight-threatening 
component of GD.  Although clinically evident only in 25-50%, almost all patients 
with GD have some degree of ocular changes that can be detected by more sensitive 
methods such as ultrasonography, computed tomographic, or magnetic resonance 
imaging.  Clinical features of GO result from changes in the orbit that consists of i) 
orbital inflammation, ii) swelling in the retrobulbar space, and iii) restriction of 
extraocular muscle motion and/or impairment of optic nerve function. 
 Swelling in the retrobulbar space is due to accumulation of 
glycosaminoglycans (GAG) by the orbital fibroblasts.  GAG is intensely hydrophilic 
and binds water causing gross enlargement of the extraocular muscles and edema of 
the surrounding connective tissues.  This increase in tissue volume within the 
confines of the bony orbit gives rise to proptosis, a forward displacement of the globe 
[14].  Restriction of extraocular muscle motion initially occurs as a result of swelling.  
At a later stage, fibrosis and atrophy due to chronic compression and inflammation set 
in [15].  In addition to the accumulation of GAG, mononuclear cells infiltrate the 
orbital tissues [16].  On histologic examinations, besides the expansion of eye muscle 
and orbital fat tissues, lymphocytic infiltrate consisting of predominantly CD4+ and 
CD8+ T cells with a few B cells can be seen.  Once stimulated, the T cells release 
numerous cytokines which bring about orbital fibroblast proliferation, induction of 
glycosaminoglycan synthesis and transformation of orbital preadipocyte fibroblasts 
into orbital fat cells.  Therefore, GO is fundamentally, an inflammatory disease of the 
orbital tissues [15, 17, 18]. 
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2.1.   T Lymphocytes (T cells) Development  
 T cells are lymphocytes that arise from stem cells in the bone marrow.  They 
leave the bone marrow at an immature stage and complete their development in the 
thymus.  Most T cells in the body belong to one of two subsets, CD8+ or CD4+ and 
their development in the thymus can be traced by surface markers.  In the thymus, the 
cells initially possess both CD8+ and CD4+ markers, making them double positive 
cells.  They eventually loose either the CD4+ or CD8+ marker to become one of the 
functional subsets. 
 All T cells possess antigen receptor molecules on their surfaces called T cell 
receptor (TcR).  Antigens are the obligatory first signals for lymphocyte activation.  
Chemically different antigens stimulate different types of immune response.  TcRs 
recognize antigens only when they have been ingested, degraded and presented on the 
surface of an antigen presenting cell (APC).  Antigens are bound to specialized 
antigen-presenting glycoprotein called major histocompatibility complex (MHC) 
molecules on the surface of the APC.  On contact with antigen presented by MHC on 
APC, T cells are activated [3].  
 CD8+ cells are cytotoxic T cells (Tc cells) and they secrete molecules that 
destroy the cell to which they are bound (Figure 8).  CD8+ T cells are activated by 
antigen peptides presented by MHC class I molecules, and are directed to destroy the 
APC by inducing them to undergo apoptosis.  Most cells express MHC class I 
molecules and therefore can present pathogen-derived peptides to CD8+ T cells if 
infected with a virus or other pathogen that penetrates the cytosol.  CD8+ T cells are 
specialized to respond to intracellular pathogens [3].  
 CD4+ T cells activate B cells towards antibody responses and macrophages 
towards microbial destruction.  They also recruit these cells to the site of infection 
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through cell-cell interactions and cytokine production.  They are essential for both the 
cell-mediated and antibody-mediated branches of the immune system.  CD4+ T cells 
recognize and are activated by antigens presented by MHC class II molecules on 
specialized APCs such as dendritic cells, macrophages and B cells, which take up and 
process material from the extracellular environment.  Because their function is 
principally to help other cells achieve their effector functions, they are often called 
helper T cells (Th cells).  CD4+ T cells can be further subdivided into helper T cell 1 
(Th1) and helper T cell 2 (Th2) [3].  
 
2.1.1.   Helper T cells 
 When helper T cells are activated by dendritic cells, they can differentiate into 
either Th1 or Th2 effector cells.  Helper cells secreting cytokines that mainly activate 
macrophages and B cells with production of opsonizing antibodies of IgG1 subclass 
are called Th1 cells.  Helper cells helping primarily in B cells antibody responses are 
called Th2 cells (Figure 8).  While Th2 cells work within secondary lymphoid tissues, 












Figure 8.   Three classes of effector T cell specialized to deal with three classes 
of pathogens. 
 
CD8+ cytotoxic T cells kill cells that present peptides derived from viruses and other 
cytosolic pathogens.  Th1 cells recognize peptides derived from pathogens or their 
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products that have been swallowed by macrophages.  Th2 cells activate naïve B cells 
and control many aspects of the development of antibody response [3].  
 Figure 9.   Activation of helper T cell and differentiation into Th 1 
cells.  
 
IFN γ produced by NK cell that was stimulated by IL-12 produced by 






















 Cytokines produced during infection or inflammation modulates the 
differentiation of helper T cells into Th1 or Th2 responses.  Interleukin 12 (IL-12) 
produced during the early stage of infection, is mainly the product of dendritic cells 
and macrophages.  It stimulates natural killer (NK) cells to produce gamma interferon 
(γIFN), which in turn stimulate differentiation of naïve CD4+ T cells into Th1 cells 
and activates macrophages (Figure 9).  In addition, IL-12 and γIFN also inhibits the 
development of Th2 cells.  Conversely, differentiation of naïve CD4+ T cells towards 
Th2 response is promoted by IL-4 which is produced by subsets of T cells and mast 
cells.  IL4 also has the property of inhibiting Th1 cell differentiation.  The 
commitment of the CD4+ T cell response towards a Th1 or a Th2 phenotype probably 
depends on the way the antigens interact with immature dendritic cells, macrophages, 
and NK cells during the early phases of an infection/inflammation and the profile of 
cytokines that is synthesized at that time.  The cytokines produced by effector Th 1 
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and Th 2 cells also tend to suppress each other’s differentiation, so that once a CD4+ 




Figure 10.   Suppression of 
Th cell by another Th cell 
which has been activated. 
Cytokines produced by one 
Th cell switches off the 
production of cytokines by 
the other Th cell, thus only 
one Th cell can be activated 











2.1.2.   Cytokines 
 Cytokines are soluble proteins secreted by T cells and other cell types in 
response to activating stimuli.  Cytokines mediate many effector functions of the cells 
that produce them.  They are the principal mechanisms by which various immune and 
inflammatory cell populations communicate with one another. 
 The cytokines secreted by Th 1 cells include γIFN, GM-CSF, TNF α, TNF β, 
IL2, IL3, CD40 ligand, and Fas ligand.  They bias towards macrophage activation, 
which leads to inflammation and a cell-mediated immune response, dominated by 
cytotoxic CD8+ T cells and/or CD4+ Th 1 cells, and macrophages.  Figure 11 shows a 












Figure 11.   Activities of an activated Th1 cell 
 
Activation of Th1 cells results in the synthesis of cytokines.  The six panels show the 
effects of different cytokines.  LT - lymphotoxin.  MCP - macrophage chemoattractant 
protein [3]. 
 
 Cytokines secreted by Th 2 cells, in contrast, induce mainly B-cell 
differentiation and antibody production.  They include IL3, IL4, IL5, GM-CSF, IL10, 
TGF β, Eotaxin, and CD40 ligand and they mediate the processes of humoral immune 
response.  This division of labor is not absolute, however, because Th 1 cells have 




Figure 12.   Th2 cells acting on naive B cells. 
 
Stimulation of naïve B cells led to proliferation and differentiation to form plasma 









2.2   Helper T cell Involved in Graves’ Ophthalmopathy 
 The inflammatory responses occurring in the orbits of GO patients have been 
studied extensively.  Characterization of T cell populations and cytokine profiles 
present in orbital tissues often yield contradicting results.  A study by Pappa et al 
reported the predominance of CD4+ T cell lines derived from extraocular muscles of 
GO patients and that both Th1 and Th2 cytokine profiles were present in their T cell 
lines [19].  Other reports showed predominance of CD8+ T cells in the orbit with 
either inconsistent cytokine profiles, a mixture of Th1 and Th2 responses or 
predominance of Th1 profile [20, 21].  The fundamental aim underlying these studies 
is the question whether cell-mediated immunity (Th1) or humoral immunity (Th2) is 
the major effector of the inflammation present in GO [22-24].  These studies into the 
balance of Th1 and Th2 responses are often confounded by problems highlighted 
below which make accurate interpretation of results difficult. 
• Difficult accessibility of orbital tissues – samples of orbital fat and muscles 
are obtained mostly at the time of surgical interventions, which are usually 
performed in the late stages of the disease when the active inflammatory 
reaction caused by the initial autoimmune attack has disappeared and fibrosis 
dominates the picture. 
• Differing techniques of investigation – In some studies, culture of T cell lines 
and T cell clones in the presence of IL2 or IL 2 and IL4 could potentially bias 
towards detection of either Th1 or Th2 responses respectively.  In this case, 
the populations of T cultured cells may not be truly reflective of the in-situ 
composition [23, 25-27].  
• Differing genetic background – GO tissue samples derived from patients are 
heterogeneous in their genetic makeup.  A complex network of genetic factors 
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governs the response of the immune system.  Genetic factors such as HLA, T 
cell regulatory gene, polymorphisms in cytokine, cytokine receptors, and toll-
like receptors have been shown to determine the type and magnitude of 
immune responses and may be important in the pathogenesis of both infective 
and autoimmune diseases [28-31].  
 
2.3.   Animal Model of Graves’ Ophthalmopathy 
 The development of an animal model of GO will to an extent avoid the 
limitations encountered in previous studies, although it is recognized that disease 
pathogenesis in animal models may differ significantly from that in human disease 
and therefore may not be directly applicable.  Experimental animals can be chosen for 
their genetic composition.  Tissue sampling can be done at specific time of onset of 
the disease and these samples will be naïve to all forms of therapeutic intervention.  
In recent years, significant progress has been made in establishing a mouse model of 
GO. Orbital inflammation has been observed in 2 models: 1) after genetic 
immunization of NMRI outbred mice treated with full length TSH receptor in an 
eukaryotic expression plasmid [32] and 2) after transfer of TSH receptor sensitized T 
cells in Balb/c mice [33]. In this current project, I used the method of genetic 
immunization for achieving the objective of inducing inflammatory responses in the 
orbit of immunized animals. 
 The GD mouse model with orbital inflammation was first successfully 
generated through genetic immunization with full length TSHR by Costagliola et. al. 
[32]. The outcome was a strong humoral response where all the immunized outbred 
mice produced antibodies capable of recognizing the recombinant receptor expressed 
at the surface of stably transfected Chinese hamster ovary (CHO) cells (JP19 cells) in 
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flow cytometry, and most had detectable levels of TSBAb activity in their serum.  
Five of 29 mice that were injected showed sign of hyperthyroidism with elevated total 
T4 and suppressed TSH levels.  In these 5 hyperthyroid mice, thyroid-stimulating 
activity was detected in the serum and there was development of goiter with extensive 
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Figure 13: Semi-thin section of the thyroid from (a) control NMRI mouse. 
x160 and (b) of thyroids immunized hyperthyroid NMRI mice, showing very 





and these animals displayed ocular signs suggestive of GO  (Figure 14) including 














Figure 14: Semi-thin sections of extraocular muscles from immunized 
hyperthyroid NMRI mice. (a) The muscular cells, in transverse section, are 
dissociated by an edema and a deposit of an amorphous material (*) or by fibrous 
tissue (+). x250.  The adipose tissue infiltrating the muscle is made of cells of 
various sizes, often in association with mast cells (arrows). 
These signs, reminiscent of features of GD and GO, demonstrated that genetic 
immunization of outbred NMRI mice with human TSHR provided the most 
convincing and closest animal model available at that point in time for GD. 
 The other mouse model of GD with orbital inflammation, generated by Many 
et. al [33],  was induced by transfer of TSHR sensitized T cells in Balb/c mice into 
syngeneic mouse.  Of the 35 Balb/c mice experimented, thyroiditis was induced in 
60-100% and the lymphocytic infiltrate comprised of activated T and B cells. 
Immunoreactivity for IL-4 and IL-10 was present.  Autoantibodies to the receptor 
such as TBII, were also induced.  A total of 17 of 25 Balb/c mouse orbits examined 
displayed changes which consisted of accumulation of adipose tissue, edema caused 
by periodic acid Schiff-positive material, dissociation of the muscle fibers, presence 





Figure 15: Balb/c ocular muscle. (a) Balb/c recipients of nonprimed T 
cells.  The histology is normal with intact muscle fibers. x320. (b) Balb/c 
recipient of TSHR-primed T cells 12 wk after transfer.  Organization of 















2.3.1.   Balb/c inbred versus Swiss Outbred mice 
 Balb/c mice are inbred strain which is produced by NUS animal holding unit.  
The strain is obtained through 20 or more consecutive generations of brother and 
sister matings with all individuals being traced from a common ancestor in the 20th or 
subsequent generation.  Inbred strains are more uniform, better defined and 
genetically more stable than outbred mice.  This strain remains genetically stable for 
many generations.  In contrast, for Swiss Outbred mice, brother and sister mating is 
avoided with the aim to maintain as heterogeneous as possible the animal population. 
In this strain, the inbreeding coefficient adopted is less than 1%.  Swiss outbred mice 
is a general-purpose mouse recommended for dissection and any work not requiring 
the special qualities of inbred strains.  
 Differences between inbred and outbred mouse responses to immunization 
had been reported previously. Where genetic immunization using TSHR cDNA [34] 
and transfer of TSHR sensitized T-cells [33] were used in inbred strain, thyroiditis 
was induced in 60-100% of the mice. Autoantibodies recognizing the native receptor 
were detected in virtually all mice sera but most displayed blocking TSBAb and TBII 
activities.  No hyperthyroidism was observed.  When genetic immunization using 
TSHR cDNA was used to generate the mouse model in outbred strain [32], 
hyperthyroidism, with elevation of total T4 and suppression of TSH levels, was 
demonstrated in 1 out of 5 mice. These mice had stimulating TSAb activity,increased 
thyroid mass with extensive lymphocytic infiltration and histological evidence of 
thyroid follicular cell hyperplasia. 
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2.3.2.   Genetic Immunization  
 Genetic immunization, also known as DNA vaccination, represents a novel 
approach for achieving specific immune activation.  It has been known for decades 
that delivery of naked DNA into an animal could lead to in vivo gene expression.  The 
concept behind genetic immunization is simple.  The gene encoding an antigen is 
cloned into a plasmid with an appropriate promotor, and the plasmid DNA is 
administered to the vaccine recipient by injection into the subcutaneous tissue or 
muscles.  The injected DNA is transfected into the dendritic cells or keratinocytes of 
the host and the latter are thought to be reservoirs for the antigen.  The resultant 
foreign protein is produced within the host cell and then processed and presented 
appropriately to the immune system, inducing a specific immune response.  
Immunization with DNA thus mimics live infection, with the antigen synthesized 
endogenously by host cells.  This synthesis leads to the induction of a cytotoxic T cell 
response via the MHC class I-restricted pathway.  Concurrently, antigen is released 
extracellularly and this process primes the induction of a humoral response, by way of 
Th response via MHC class II-restricted antigen presentation by APCs that have taken 









Figure 16.   Plasmid 
DNA immunization.  
 
Plasmid injected intra 
muscularly, transfect 
dendritic cell and 
keratinocyte.  Antigen 
presented to naïve 
CD4+ T cell.  T cell 
activated and 
differentiates to 
effector T cells which 
activate CD8+ and B 
cells. 
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2.3.3.   Timing of blood and tissue sampling 
 In a study by Tang et al [35], genetic immunization of gene encoding protein 
of interest was used as a method to elicit an immune response in mice.   Young mice 
(8-15 weeks old) were used and antibodies directed against gene of interest were 
detectable in most mice within 2 weeks of first immunization.  The study concluded 
that primary response could be augmented by a subsequent 2nd and 3rd DNA boosts 
although there was no recommendation on the timing interval of these boosters.  In 
our study, the 2nd and 3rd DNA boosts took place at day 28 and day 56 respectively 
after the initial immunization and blood sampling was done 5 days prior to initial 
immunization and at sacrifice at day 112 for detection of sera antibodies against the 
TSHR. These time lines followed the immunization protocol described by Costagliola 
et al [32].  In a previous publication by Costagliola [36], histological changes 
showing atypical lymphoblastoid infiltration and follicular destruction of thyroids 
was already observed at day 49 after immunization with extracellular domain of the 
human TSHR in Balb/c mice.  In another publication also by Costagliola [32], using 
genetic immunization of outbred NMRI mice with cDNA encoding the human TSHR, 
changes in the thyroid with extensive lymphocyte infiltration and ocular signs 
suggestive of GO were also seen in sectioned and stained tissues at day 112 during 
sacrifice.  
 
2.4.   Cytokine Profile Study using Real-Time PCR, TaqMan® Technology 
 Real-Time PCR is a sensitive and specific means of quantifying a gene of 
interest.  It has the ability to monitor the progress of the PCR as it occurs because data 
is collected throughout the PCR process, rather than at the end of the PCR.  In real-
time PCR, reactions are characterized by the point in time during cycling when 
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amplification of a target is first detected rather than the amount of targets 
accumulated after a fixed number of cycles.  The higher the starting copy number of 













 The fluorescence-monitoring system for DNA amplification used in our 
experiments is TaqMan® probe.  The probe consists of a short single strand of 
polynucleotide linking 2 fluorophores (Figure 18).  When in close proximity, before 
the DNA polymerase acts, the quencher (Q) fluorophore reduces the fluorescence 
from the reporter (R) fluorophore by means of fluorescence resonance energy transfer 
(FRET).  This is the inhibition of one dye caused by another without emission of a 





Figure 18.   TaqMan® probe 
 
The red circle represents the 
Quencher that suppresses the 
emission of signal from the 
Reporter dye (blue circle) when 





Figure 17.   Amplification 
curve 
 
Rn is the measure of reporter 
signal.  Threshold is the point 
of detection.  Cycle threshold 
(CT) is the cycle at which 
sample crosses threshold.  
CT1 which is more 
concentrated requires fewer 
cycles for fluorescence 
detection as compared to CT2.
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 Once the TaqMan® probe has bound and the primers anneal to specific places 
at the DNA template, Taq polymerase then adds nucleotides and displaces the 
Taqman® probe from the template DNA.  This allowed the reporter to break away 
from the quencher and to emit its energy, which is then quantified by the instrument 
(Figure 19).  The greater the number of cycles of PCR takes place, the higher the 



















Figure 19.   Principles of 
TaqMan®
 
First there is specific annealing 
of probe and PCR primers to the 
cDNA.  Then, primer extension 
by Taq DNA polymerase causes 
hydrolysis of TaqMan® probe.  
Probe is cleaved and displaced 
from template.  Once the probe 
is cleaved, the reporter dye is 
allowed to emit its energy 
which can be detected by the 
machine.  The signal increases 
in proportion to the number of 




 Relative quantitation is a method of quantitation where the amount of target 
gene expression in a sample is expressed in relative quantity to another sample.  The 
latter, known as a calibrator, can either be an external standard (serial dilution of a 
positive sample) or a reference sample (a negative sample or untreated sample).  
Results of such quantitation are expressed in target to reference ratios.  A control 
gene, usually a housekeeping gene (e.g. β-actin, ribosomal RNA, GADPH) is co-
amplified in the same tube in a multiplex assay in order to correct for sample-to 
sample variation in input material.  Such control genes that may also serve as positive 
controls for the reaction.  An ideal control gene is one which is expressed in a 
uniform fashion regardless of experimental conditions, sample treatment, origin of 
tissue/cell types, and developmental staging.  The comparative Ct (cycle threshold) 
method is used to calculate changes in gene expression as relative fold difference 
between an experimental sample and a calibrator sample using the formula 2-∆∆Ct 
where 2 is the ‘efficiency’ of the amplification, ∆∆Ct = ∆Ct (sample) - ∆Ct 
(calibrator), and ∆Ct is the Ct of the target gene subtracted from the Ct of the 
housekeeping gene. 
 For example, one may wish to evaluate the change in a particular gene 
expression (S) in treated and untreated samples.  For this hypothetical study, one can 
choose the untreated sample as the calibrator sample and a housekeeping gene (H) to 
normalize input amount of RNA material.  For both treated and untreated samples, 
the Ct values of both target and housekeeping genes can be obtained and ∆Ct 
calculated by the formula: (CtS – CtH) which is the difference between target gene and 
housekeeping gene. The ∆∆Ct is then subsequently obtained by subtracting ∆Ct of 
treated sample from that of calibrator sample, i.e. the untreated sample. The relative 
fold change between the two samples is then obtained using the formula of 2-∆∆Ct. 
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II.   AIMS OF STUDY 
 
 GO is an important and frequent complication of GD.  It not only affects 
quality of life of patients but can be potentially sight threatening.  There is currently 
no option of preventive treatment and management consists mainly of amelioration of 
inflammatory processes which are usually well underway once clinical presentations 
become overt.  The pathogenesis of GO remains controversial and the study of the 
inflammatory processes and cytokine profiling in human tissue samples fraught with 
difficulties as highlighted in the earlier sections.  Knowledge of the events in the 
immunopathogenesis of GO is required if the use of specific immunological 
interventions is desired.  Therefore, understanding the nature of cytokine events is 
important in ameliorating or even halting the onset of GO.  Cytokines effects can be 
blocked not only by corticosteroids but also by antagonists such as IL-1 receptor 
antagonists.  Indeed, specific immunomodulatory therapies (anti TNF-α and other 
anti-cytokines) have shown promise in treatment of other immune diseases such as 
Crohn’s disease and rheumatoid arthritis [37, 38].  These treatment modalities may 
prove to be valuable to GO as well since there is currently no satisfactory and 
effective therapy available to stop the progression of this disabling and sight-
threatening illness. Therefore, a mouse model of GD and GO presents a unique 
and attractive opportunity to study the immunological events following immunization 
of animals with human TSHR in a controlled and specific manner.  In this study, the 
following objectives were undertaken: 
1. To genetically immunize 2 strains of mice, specifically Swiss outbred and 
Balb/c inbred mice, with the human TSHR. 
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2. To evaluate the production of anti-TSHR antibodies (TRAB) by measuring 
the TBII, TSAB and TSBAB in these immunized animals 
3. To obtain relative quantities, by real-time PCR, of Th1 and Th2 cytokines 
present in the thyroidal, splenic and orbital tissues of mice immunized with 
the human TSHR and controls which were injected with empty plasmid. 
4. To correlate the changes in cytokine gene expression with various TRAB 
measurements. 
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III.   MATERIALS AND METHOD 
 














Figure 20.   Schedule for genetic immunization and blood/tissue collection 
 
 Two strains of 6-7 weeks old female mice, Swiss outbred and Balb/c inbred, 
were studied.  We immunized 20 Balb/c and 15 Swiss outbred mice. Five from each 
strain served as controls, while 15 and 10 mice respectively in each strain were 
immunized with TSHR. From previously reported studies [32, 34] almost all mice 
immunized generated antibodies against the native TSHR.  Seventy five percent of 
these mice were positive for blocking TSBAb antibody while 17% positive for 
stimulating TSAb antibody.  This gives the probability of obtaining 19 and 14 mice 
positive for TSHR antibody in inbred and outbred strains respectively for the study.  
Moreover, sample size of 15 to 20 mice was an optimal number for efficient 
experimental and tissue handling i.e, immunization, blood sampling and tissue RNA 
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on biochemical testing, the study cohort would generate 2 to 3 hyperthyroid mice. 
However, we believe that RT-PCR is a far more sensitive method for detection of 
cytokine changes and will be able to detail alterations in cytokine profile between 
control and test animals. 
 Experimental mice were injected on Day 0 in the anterior tibialis muscle with 
100 µg of human TSHR cDNA in pcDNA3 plasmid dissolved with PBS after 
pretreatment 5 days earlier (- Day 5) with 100µl cardiotoxin 10µM, purified from 
venom of Naja nigricollis; (Latoxan, Valance, France).  Control mice were injected 
with empty plasmid.  Injections were repeated on D28 and D56 after the first 
immunization [34].  Blood samples of ~ 200μl were collected via tail vein before the 
first injection (-D5) and subsequently at sacrifice by cardiac puncture on D112.  Sera 
samples were used for testing of TRAB antibodies and thyroid hormone levels.  
During sacrifice, the thyroid lobe, the contents of the orbit and the spleen were 
removed and preserved with RNALaterTM for RNA extraction.  This was used 
subsequently for cytokine profile study using Real-Time PCR technique. 
 
2.   Sera Characterization 
 
 Blood collected on – Day 5 and Day 112 were spun down and the sera used 
for TRAB detection using methods of flow cytometry, TBII, TSAB and TSBAB 
assays.  Total T4 levels in the sera were measured using clinical total T4 human assay 
(Vitros® Eci Immunodiagnostic Systems, Ortho-clinical Diagnostics, Rochester, NY) 
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2.1.   Flow Cytometry 
 CHO cells expressing full length human TSHR (JP19) was used.  These 
adherent cells were detached using EDTA/EGTA (5mM each) in 1 x PBS.  150,000 
cells/tube were transferred into Falcon 2052 tubes and washed in 3ml of 1 x PBS.  
Cells were pelleted at 500 x g, at 4oC for 3min, and supernatant was removed by 
inversion.  Cells were incubated for 30 min at room temperature in 100µl PBS-BSA 
0.1% containing 5µl (5%) mouse serum.  The cells were then washed in 3ml of 1 x 
PBS/0.1% BSA, centrifuged and supernatant removed as above, incubated for 30 min 
in the dark and on ice with 2µl fluorescein-conjugated γ-chain-specific goat anti-
mouse IgG (Sigma Chemical Co., St. Louise, MO) in the same buffer.  Propidium 
iodide (10µg/ml) was used for detection of damaged cells, which were excluded from 
the analysis.  Cells were washed once again and supernatant removed as above and 
resuspended in final volume of 250µl in 1 x PBS/0.1% BSA.  The fluorescence of 
10,000 cells/tube was assayed by a FACScan flow cytometer (Becton Dickinson, 
Eerenbodegem, Belgium) [34]. 
2.2.   TBII   
 TSH-binding inhibiting activity was also measured on JP19 cells [34].  
Briefly, 5 x 104 cells/well were plated onto 96-well plates one day prior to 
experiment.  Cells were incubated in 95µl of TBII Binding Buffer (5.4mM KCl, 
0.44mM KH2PO4, 0.47mM MgSO4, 0.35mM Na2HPO4, 1.3mM CaCl2, 0.1% glucose, 
9.5% sucrose, 5% BSA, pH 7.4), 30,000cpm TSHI-125 and 5µl mouse serum/well 
(5%), for 4 hours at room temperature.  At the end of the incubation period, the cells 
were rapidly rinsed twice with the same ice-cold buffer and finally solubilized with 
0.2ml 1N NaOH before radioactivity was measured in a gamma counter.  All 
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experiments were done in triplicate, and results are expressed as cpm bound. The 
stronger the TBII activity, the lower the cpm of bound TSHI-125  
 
2.3   TSAB and TSBAB  
 TSAB and TSBAB activities were measured using JP19 [34].  Briefly, 3 x 104 
cells/well in 96-well plates were rinsed with Krebs-Ringer-HEPES (KRH) buffer 
(124mM NaCl, 5mM KCl, 0.25mM KH2PO4, 0.5mM MgSO4, 0.4mM Na2HPO4, 
1mM CaCl2, 0.1% glucose, 20mM HEPES, and 0.3% BSA, pH 7.4) before being 
incubated in the same buffer, together with 25µM Rolipram and 5µl of serum in a 
total volume of 100µl/well.  The cells were incubated for 4 hour at 370C.  Cyclic 
AMP released into the medium was measured using a competitive binding assay kit 
(Perkin Elmer, Wellesley, MA).  TSAB was measured under basal conditions 
described above while TSBAB was measured in identical condition, but with the 
addition of 10mIU/ml final concentration bovine TSH (Sigma Chemical Co. St. 
Louise, MO). Triplicate samples were assayed in all experiments.  Commercial kits 
measuring cAMP were used (Perkin Elmer, Wellesley, MA) and results are expressed 
as pmol/ml.  In measurement of TSBAB in sera, the higher the TSBAB activity level, 
the smaller the result in pmol/ml.  In TSAB activity measurement in sera, the higher 
the activity, the higher the result in pmol/ml. 
 
3.   Cytokine Profile 
 
 Using Real-time PCR and TaqMan® probe techniques on cDNA reverse 
transcribed from RNA, gene transcription in spleen, thyroid and orbit were measured 
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to define the relative amount of Th1 (γIFN, IL2) and Th2 (IL4, IL5) cytokines present 
in immunized and non-immunized mice. 
 
3.1.   RNA Extraction 
 The area of the eye that was taken for RNA extraction was area 2 and 3 shown 
in figure 21 below.  The weight of a normal eye of a mouse ranges from 14 to 24 mg 
[39]. It is technically difficult to distinguish orbital contents, such as fat from muscle, 
without compromising RNA integrity.  For this reason, the entire content of the eye 
was enucleated and placed immediately in RNA LaterTM , a reagent used to preserve 
RNA in the tissue.  Care was taken to prevent too much dissection and cutting of 
tissue to minimize RNase release into the tissue which can lead to RNA degradation. 
 
Figure 21: The eye of a 








 Tissues obtained at sacrifice were first weighed before RNA was extracted 
following manufacturer’s protocol with a few modifications.  Briefly, 100mg tissue 
was homogenized in 1ml TRIZOLTM (Invitrogen Corp, Carlsbad, CA), using 
PowerGen 125 (Fisher Scientific, Hampton, NH), passed through a 21G needle, 
centrifuged at 14,000g for 10 min at 4 0C to pellet DNA and non-homogenized tissue, 
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with final addition of 0.2ml Chloroform (Sigma Chemical Co. St. Louise, MO).  The 
aqueous layer was pipetted into a Phase-Lock-GelTM (Eppendorf, Hamburg, 
Germany) tube and extraction was done using Acid Phenol (Ambion, Austin, TX).  
Phase-Lock-GelTM Tube was used for Acid Phenol extraction to minimize loss of 
aqueous phase.  Subsequently, 2 Chloroform: Isoamyl Alcohol (24:1) (Sigma 
Chemical Co., St Louise, MA) extraction steps were done in normal 2.0 ml microfuge 
tubes with back extractions to maximize recovery of aqueous layer.  Aqueous layer 
recovered from these phenol chloroform steps are DNA free because contamination 
from the DNA containing interphase layer was avoided.  RNA was precipitated using 
equal volume of Isopropanol (Sigma Chemical Co., St Louise, MA) and 0.8M 
Disodium Citrate /1.2M Sodium Chloride (Sigma Chemical Co., St Louise, MA) and 
pelleted by centrifuging at 14,000g for 10 min at room temperature.  RNA pellet was 
washed twice using 70% Ethanol (Sigma Chemical Co., St. Louise, MA) and air dried 
for 7 min before RNase free water was added.  Extracted RNA was frozen overnight 
in minus 700C deep freezer.  The next day, dissolved RNA sample was measured on 
spectrophotometer to determine the concentration and ran on 1% native agarose gel to 




3.2.   Reverse Transcription   
RNA was reverse transcribed using SuperScriptTM III First-Strand Synthesis 
System for RT-PCR (Invitrogen, Carlsbad, CA), following manufacturer’s protocol.  














Component Volume µl/reaction 
Total RNA + RNase DNase free H20 8 
Primer (50µM oligo dT) 1 
10mM dNTP mix 1 
 
Incubate at 65oC for 5 min, then place on ice for at least 1 min.  Prepare the 
following cDNA Synthesis Mix, adding each component in the indicated order. 
10 x RT buffer 2 
25 mM MgCl2 4 
0.1 M DTT 2 
RNase OUTTM (40U/µl) 1 
SuperScriptTM III RT (200u/µl) 1 
 
Add 10µl of cDNA Synthesis Mix to each RNA/primer mixture, mix gently, 
and collect by brief centrifugation.  Incubate as follows. 
50 min at 50oC 
5 min at 85oC 
 
Chill on ice.  Collect the reactions by briefly centrifugation. 
Add 1µl of RNase H to each tube and incubate for 
20 min at 37oC 
The resulting cDNA was directly used for Real-time PCR. 
Table 2.   Conversion of RNA to cDNA 
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3.3.   Real-Time Polymerase Chain Reaction (PCR)  
 Real-Time PCR was carried out using the TaqMan® Gene Expression Assays 
(20x) (Applied Biosystems, Foster City, CA).  This assay consisted of two unlabeled 
PCR primers and a FAMTM dye-labeled TaqMan® MGB (minor groove binder) probe.  
Assays for genes IL2, IL4, IL5 and γIFN in Mus musculus were done.  Each cytokine 
was multiplexed with β-actin, the housekeeping gene.  These pre-designed gene 
specific Taqman® probes and primers which have been previously manufactured and 
passed quality control specifications, are proprietary designs owned by Applied 
Biosystems.  These kits were used together with TaqMan® Fast Universal PCR 
Master Mix (2x) (Applied Biosystems, Foster City, CA) and ran on 7900HT Fast 
Real-Time PCR System (Applied Biosystems, Foster City, CA).  Each sample was 
prepared in a mixture detailed in table 3. 
 
Components Volume µl/reaction 
Mouse β-actin Endogenous Control (20x) 0.25 
TaqMan Gene Expression Assay (20x) 0.5 
TaqMan Fast Universal Master Mix(2x) 5 
cDNA template + dH20 4.25 
 
Cycling Conditions according to manufacturer’s protocol 
20sec        950C 
40 cycles of 
1 sec         950C 
20 sec       600C 
 











 Relative quantification using the comparative method was used to analyze the 
data output.  To determine the change in cytokine expression after immunization with  
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 TSHR, the 2-∆∆Ct formula was applied.  Samples from mice injected with TSHR were 
the experimental samples while samples from control mice served as calibrator 
samples.  Results were reported as relative fold change of experimental sample over 
control sample.  In determining relative Th1 or Th2 dominance, we calculated the 
fold changes were calculated using Th2 cytokines as the experimental samples with 
Th1 cytokines as the calibrator.  A fold change of >1 meant that experimental 
samples had increase in expression over the calibrator samples while a fold change of 
<1 meant a decrease in expression. 
 
 
4.   Statistical Analyses 
 
 Data were analyzed and graphs plotted using SPSS version 9.0 software.  
Non-parametric data were expressed as median and inter-quartile ranges (25% 
to75%).  Analyses of differences between groups were done using Mann-Whitney 
test. Linear regression equation was obtained using stepwise, enter method.  Cross 
tabulation statistics were tested with Chi-square test. A p-value of <0.05 was taken as 
statistically significant.
 37
IV.   RESULTS 
 
1.   RNA Extraction 
 
 Absorbance readings and ratios for all tissue extracted were tabulated as 
shown in tables 4, 5,6,7,8 and 9.  It is ideal that A260/280 ratio be between 2.00 and 
2.20 indicating clean RNA preparations. 
 
Table 4.   Absorbance readings for spleen RNA in Balb/c mice. 
Spleen mg dilution A260 A280 A260/280 Conc.(mg/ml) 
V1 107 100 0.704 0.323 2.178 5.65 
V2 164 100 1.964 0.932 2.107 15.71 
V3 115 100 0.931 0.432 2.154 7.45 
V4 192 100 1.171 0.540 2.169 9.37 
V5 155 100 1.053 0.490 2.150 8.43 
2R1 105 100 0.623 0.281 2.220 4.98 
2R2 131 100 0.875 0.399 2.192 7.00 
2R3 111 100 0.925 0.423 2.188 7.40 
2R4 100 100 0.603 0.272 2.216 4.83 
2R5 65 100 0.650 0.300 2.180 5.21 
3R1 108 100 0.675 0.305 2.214 5.40 
3R2 82 100 0.990 0.450 2.210 7.97 
3R3 53 100 0.740 0.330 2.210 5.93 
3R4 76 100 0.820 0.370 2.210 6.53 
3R5 128 100 0.830 0.380 2.220 10.00 
4R1 160 200 0.670 0.300 2.235 5.36 
4R2 130 200 1.026 0.467 2.199 8.21 
4R4 142 400 0.868 0.410 2.118 13.88 








Table 5.   Absorbance readings for thyroid RNA in Balb/c mice. 
Thyroid mg dilution A260 A280 A260/280 Conc.(mg/ml) 
V1 58 100 0.424 0.187 2.260 1.69 
V2 55 100 0.412 0.215 2.145 1.85 
V3 72 200 0.353 0.156 2.260 1.41 
V4 39 100 0.285 0.127 2.240 0.57 
V5 109 100 1.436 0.669 2.146 5.74 
2R1 136 100 0.870 0.396 2.196 3.48 
2R2 39 50 0.554 0.255 2.177 1.11 
2R3 47 50 0.847 0.389 2.180 1.69 
2R4 80 200 0.385 0.315 2.179 5.48 
2R5 47 50 0.726 0.338 2.147 1.45 
3R1 48 100 0.518 0.236 2.192 2.07 
3R2 40 50 0.448 0.205 2.192 0.90 
3R3 60 100 0.991 0.460 2.156 3.96 
3R4 92 200 0.868 0.397 2.187 6.94 
3R5 34 50 0.550 0.252 2.184 1.10 
4R1 83 100 0.590 0.270 2.186 2.39 
4R2 104 100 0.696 0.311 2.241 2.79 
4R4 102 100 1.048 0.474 2.210 4.19 








Table 6.   Absorbance readings for orbit RNA in Balb/c mice. 
Orbit mg dilution A260 A280 A260/280 Conc.(mg/ml) 
V1 47 50 0.809 0.366 2.207 1.62 
V2 200 100 0.761 0.344 0.209 3.04 
V3 80 50 0.833 0.377 2.209 1.67 
V4 66 50 0.640 0.291 2.200 1.28 
V5 49 50 0.650 0.299 2.173 1.30 
2R1 67 50 0.669 0.366 2.185 1.34 
2R2 55 50 0.644 0.290 2.217 1.29 
2R3 61 50 0.685 0.310 2.206 1.37 
2R4 86 50 0.864 0.394 2.195 1.73 
2R5 74 50 0.721 0.326 2.208 1.44 
3R1 78 50 0.653 0.290 2.255 1.31 
3R2 77 50 0.614 0.275 2.234 1.23 
3R3 61 50 0.450 0.193 2.330 0.90 
3R4 61 50 0.654 0.289 2.265 1.31 
3R5 54 50 0.745 0.334 2.233 1.49 
4R1 59 50 0.641 0.283 2.262 1.28 
4R2 78 50 0.748 0.328 2.278 1.50 
4R4 84 100 0.438 0.186 2.353 1.75 




Table 7.   Absorbance readings for spleen RNA in Swiss Outbred mice. 
Spleen mg dilution A260 A280 A260/280 Conc.(mg/ml)
V1 110 100 0.836 0.393 2.127 3.34 
V2 54 100 1.606 0.712 2.164 6.43 
V3 73 100 0.680 0.314 2.168 2.72 
V4 98 100 1.070 0.497 2.155 4.28 
V5 76 100 0.828 0.387 2.141 3.31 
WT1 98 100 1.356 0.637 2.130 5.42 
WT2 108 200 0.889 0.409 2.171 7.12 
WT3 66 100 0.572 0.263 2.172 2.29 
WT4 74 100 0.812 0.383 2.122 3.25 
WT5 105 200 0.742 0.341 2.172 5.94 
WT6 59 100 0.893 0.413 2.163 3.57 
WT7 93 100 0.940 0.440 2.136 3.76 
WT8 173 100 1.483 0.691 2.146 5.93 
WT9 103 100 0.953 0.442 2.156 3.81 
WT10 107 100 1.156 0.540 2.143 4.63 
 
 
Table 8.   Absorbance readings for thyroid RNA in Swiss Outbred mice. 
Thyroid mg dilution A260 A280 A260/280 Conc.(mg/ml)
V1 3 50 0.153 0.071 2.142 0.31 
V2 20 100 0.271 0.124 2.180 1.08 
V3 11 100 0.076 0.034 2.226 0.30 
V4 24 100 0.289 0.131 2.212 1.15 
V5 42 100 0.352 0.162 2.173 1.41 
WT1 39 100 0.393 0.179 2.197 1.57 
WT2 53 100 0.395 0.181 2.180 1.58 
WT3 41 100 0.324 0.147 2.200 1.30 
WT4 42 100 0.700 0.323 2.167 2.80 
WT5 35 100 0.138  0.052   2.645 0.55  
WT6 28 100  0.178  0.066  2.714  0.71 
WT7 67 100  0.211  0.079  2.668  0.84 
WT8 25 100  0.206  0.080  2.564  0.82 
WT9 41 100  0.290  0.137  2.120  1.16 
WT10 42 100  0.448  0.194  2.307  1.74 
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Table 9.   Absorbance readings for orbit RNA in Swiss Outbred mice. 
Orbit mg dilution A260 A280 A260/280 Conc.(mg/ml)
V1 36 100 0.353 0.149 2.363 1.41 
V2 41 100 0.345 0.150 2.303 1.38 
V3 53 100 0.439 0.196 2.238 1.76 
V4 38 100 0.447 0.206 2.166 1.79 
V5 54 100 0.420 0.189 2.224 1.68 
WT1 58 100 0.467 0.213 2.191 1.87 
WT2 73 100 0.400 0.181 2.212 1.60 
WT3 53 100 0.392 0.177 2.218 1.57 
WT4 53 100 0.447 0.202 2.214 1.79 
WT5 49 100 0.394 0.176 2.238 1.58 
WT6 51 100 0.415 0.186 2.225 1.66 
WT7 30 100 0.455 0.208 2.189 1.82 
WT8 44 100 0.322 0.144 2.236 1.29 
WT9 55 100 0.429 0.201 2.133 1.72 
WT10 48 100 0.350 0.160 2.183 1.40 
 
 
RNA integrity was check on native agarose gel (Figure 22). 
 
Figure 22.   RNA on 1% native agarose gel. 
First and last lanes are GeneRuler™ 1kb DNA Ladder (Fermentas, Ontario, 
Canada) with picture of bands and sizes shown.  Lanes in between are Total 


















2.  Immunization of Balb/c and Swiss Outbred Mice 
 
 Mice were immunized with either an empty vector (control group) or vector 
containing TSHR expressing gene (treated group).  Twenty Balb/c mice were 
injected, 5 with empty vector and 15 with TSHR.  One mouse 4R3 died during the 
protocol before sacrifice.  Five Swiss outbred mice were injected with empty vector 
and 10 were injected with TSHR making a total of 15 Swiss outbred mice injected.  
All results are expressed as median and interquartile ranges are in parentheses. 
 
2.1   Weight 
 Weight changes in the two strains of mice are shown in Table 4.  Control and 
treated mice were comparable at the beginning and at the end of the experiment 
(Figure 23).  Both control and treated Swiss outbred mice showed increase in weight 
at the end of experiment (p<0.05), while Balb/c mice did not show any significant 








Figure 23.   Weight of mice at the start and the end of protocol. 
 
Weight in gram for control (vector) and treated (injected with TSHR) group at 
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2.2   Total T4 
 There were no significant differences in Total T4 level between the control 
and treated group of both the inbred and outbred strains (Table 11, Figure 24).  Five 
Balb/c mice had Total T4 above the range of Total T4 recorded for control mice and 1 
mouse had lowered total T4 below this range. 
 In Swiss outbred mice, 2 mice had Total T4 above the ranges for control mice 










      
Table 11.  Total T4 median for control and treated mice 
Mice Method Total T4 (pmol/L ) at sacrifice 
Significance of change 
(compared to control) 
Balb/c Vector 40.5 (23.9-43.8) - 
Balb/c TSHR 57.0 (44.8-70.4) Not Significant 
Outbred Vector 60.2 (56.1-84.7) - 





























































Figure 24.   Total T4 measurement in Balb/c and Swiss outbred 
 
No significant difference between the control and treated group of both strains. 
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2.3   FACS for TRAB Detection 
 Most of the treated Swiss outbred mice contained autoantibodies which 
recognize native TSHR expressed on stable cell line, JP19.  The median Fluorescence 
Unit of 37.4 in treated mice was compared to 7.2 in control mice was statistically 
significant.  In contrast, there was no significant difference in the fluorescence unit 





Mice Method Fluorescence Unit 
(FU) at sacrifice 
Significance of change 
(compared to control) 
Balb/c Vector 6.1 (4.4 – 8.4) - 
Balb/c TSHR 5.0 (4.2 – 8.9) Not Significant 
Outbred Vector 7.2 (5.9 – 8.7) - 
Outbred TSHr 37.4 (11.7 – 56.5) <0.05 














Figure 25.   TRAB level detection using FACS. 
 
Significant detection of TRAB level in treated Swiss outbred mice and no 





















2.4   TBII Assay 
 In Swiss outbred mice, a significant change (p<0.005) was observed between 
control and treated group.  Sera of treated mice showed considerable TBII activity 
with a median of 74.5% (interquartile range of 45.9-85.9%), relative to median of 
100% for controls (interquartile range of 97.2-100%)  In Balb/c mice however, there 






Mice Method TBII (%) at sacrifice Significance of change 
(compared to control) 
Balb/c Vector 86.0 (81.0 – 93.5) - 
Balb/c TSHR 86.0 (76.0 – 97.5) Not Significant 
Outbred Vector 100.0 (97.2 – 100.0) - 
Outbred TSHr 74.5 (45.9 – 85.9) <0.005 















Figure 26.   TBII activity in Balb/c and Swiss Outbred 
 
No significant difference between control and treated groups of Balb/c.  In Swiss 




















 2.5   TSAB and TSBAB Bioassay 
 Results were calculated as percentage (%) of control average for both TSAB 
and TSBAB cAMP production.  No significant difference in cAMP production was 






































Mice Method TSAB (%) at  Significance of change 
sacrifice (compared to control) 
Balb/c Vector 67.1 (61.0 – 155.5) - 
Balb/c TSHR 156.5 (50.8 – 291.7) Not Significant 
Outbred Vector 87.7 (84.1 – 122.0) - 
Outbred TSHr 82.5 (58.2 – 126.5) Not Significant 
Figure 27.   TSAB activity in Balb/c and Swiss Outbred 
 
No significant difference between control and treated groups for both Balb/c 
and Swiss Outbred mice. 
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 In the case of TSBAB, no significant difference between control and treated 
group of Balb/c mice was observed, while there was a significant difference (p<0.05) 
between control and treated group in the Swiss Outbred mice.  In the treated group of 
Swiss Outbred, the median was 100.6% with an interquartile range of 81-111.3%, 
while the control group had a median of 136.2% with interquartile range of 112.2-




Mice Method TSBAB (%) at  
sacrifice 
Significance of change 
(compared to control) 
Balb/c Vector 104.2 (67.9 – 130.0) - 
Balb/c TSHR 126.5 (17.5 – 135.8) Not Significant 
Outbred Vector 136.2 (112.2 – 139.7) - 
Outbred TSHr 100.6 (81.0 – 111.3) <0.05 


















Figure 28.   TSBAB activity in Balb/c and Swiss Outbred 
 
No significant TSBAB activity between control and treated groups in Balb/c 
but in Swiss Outbred mice, there is significant difference between the control 






















 Cut off for TRAB measurements were set at > 2 Standard Deviations (SDs) 
away from mean of control mice.  Table 16 showed cut off values for a parameter to 
be considered positive. 
 
 
Balb/c Positive if value is Swiss outbred Positive if value is 
FACS >10.8 FACS >10.6 
TBII <71.4% TBII <93.9% 
TSAB >201.9% TSAB >141.2% 
TSBAB <27.5% TSBAB <98.8% 









 On FACS, only 1 was positive out of 14 treated Balb/c mice, while 8 out of 10 
Swiss outbred were positive on FACS for autoantibodies recognizing TSHR (Table 
17).  TBII activity was present in 3 out of 14 Balb/c mice and in 9 out of 10 Swiss 
Outbred Mice, injected with TSHR (Table 18).  The differences across strains were 
statistically significant.  cAMP production detection for TSAB activity showed 5 of 
13 positive Balb/c mice and 2 of 10 Swiss outbred mice positive with circulating 
TSAB (Table 19).  TSBAB detection showed 5 out of 14 treated Balb/c group were 
positive while 5 out of 10 treated Swiss Outbred mice were positive (Table 20).  The 
difference in TSAB and TSBAB were not significant across strains. 
 
 




Balb/c 13 1 14 
Swiss outbred 2 8 10 
Total 15 9 24 
Table 17.   Cross tabulation of FACS status in the 2 strains of 
mice immunized with TSHR 
















TBII status Mouse strain 
negative positive 
Total 
Balb/c 11 3 14 
Swiss outbred 1 9 10 
Total 12 12 24 
Table 18.   Cross tabulation of TBII status in the 2 strains of 
mice immunized with TSHR 













 TSAB status Mouse strain 
negative positive 
Total 
Balb/c 8 5 13 
Swiss outbred 8 2 10 
Total 16 7 24 
Table 19.   Cross tabulation of TSAB status in the 2 strains of 
mice immunized with TSHR 












 TSBAB status Mouse strain 
negative positive 
Total 
Balb/c 9 5 14 
Swiss outbred 5 5 10 
Total 14 10 24 
Table 20.   Cross tabulation of TSBAB status in the 2 strains of 
mice immunized with TSHR 













3.   T cell Cytokine Profile using Real-Time PCR 
 
 Cytokine levels for spleen, thyroid and orbit were obtained using Real-time 
PCR and results expressed as fold difference between the treated and the control 
groups in both Balb/c and Swiss outbred (Table 21).  In comparing the cytokine 
levels in the treated Balb/c and Swiss strain of mice, we found significant difference 
in expression in IL4 and IL5 in the spleen (p <0.05 and p <0.005 respectively) (Table 
21, †), IL2 and γIFN in the thyroid (p<0.05 for both) (Table 21, †), IL4 and γIFN in 
the orbit (p<0.005) (Table 21, †). 
 Within each genetic strain, statistically higher expression of γIFN (in thyroid) 
and lower expression of IL5 (in orbit) were found in treated Balb/c mice (Table 21, 
**).  In Swiss outbred, IL5 expression was higher in the spleen and thyroid of treated 
Swiss outbred compared to control.  In contrast, expression of IL4, IL5 and γIFN 
were all lower in the orbit of TSHR injected (treated) Swiss outbred mice compared 



































Table 21.   Relative fold change of cytokine in Balb/c and Swiss outbred mice 
injected with TSHR compared to controls 
 
**Significant difference (p < 0.05) between TSHR injected and control Balb/c mice. 
**Significant difference (p < 0.05) between TSHR injected and control Swiss mice. 
† Significant difference (<0.05) between Balb/c and Swiss outbred mice in spleen. 
† Significant difference (<0.05) between Balb/c and Swiss outbred mice in thyroid. 
† Significant difference (<0.05) between Balb/c and Swiss outbred mice in the orbit. 
Interquartile range in parentheses.   
 
Tissue cytokine Balb/c Median 
Swiss outbred Significant difference, P 
Median (comparison of 2 strains) 




IL2 1.30 (0.65-1.87) 
0.87 
(0.80-1.20) Not Significant 





γ IFN 1.81 (0.98-2.56) 
1.06 
(0.99-1.42) Not Significant 
IL4 0.63 (0.26-0.88) 
0.58 
(0.40-1.04) Not Significant 




IL5 0.61 (0.44-1.03) 
1.81** 
(1.38-2.73) Not Significant 
Thyroid 








IL2 1.12 (0.59-2.68) 
0.53 
(0.33-0.92) Not Significant 
IL5 0.71(0.49-0.92) 
0.60** 
(0.56-0.91) Not Significant 
** Orbit 





3.1.   Correlation of Cytokines with TRAB Measurements in Balb/c Mice 
 In spleen of treated Balb/c mice, there is correlation between γIFN and 
TSBAB with p<0.05.  The stronger the TSBAB activity (the smaller the value), the 
greater the fold increase for γIFN (Figure 29).  Correlation between IL2 and TBII was 
significant where a decline in IL2 fold change was observed with TBII activity 





































Figure 29.   Correlation between γ IFN and TSBAB in spleen of Balb/c. 
 
γ-IFN correlated with TSBAB in mice positive for blocking antibodies (p<0.05) 





































were calculated as 






































spleen2 = -1.64 + 0.03 * pctbii
R-Square = 0.47
 
Figure 30.   Correlation between IL2 and TBII in spleen of Balb/c. 
 
IL2 correlated with TBII with a p value of <0.05.  The stronger the TBII, 
the fold change in IL2 decline. 
P < 0.05,
TBII results were 
calculated as 
percentage (%) of 
control average. 
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 In the orbit, correlation between IL2 and TSBAB was significant (p<0.05).  
The stronger the TSBAB activity, the greater the fold increase in IL2 (Figure 31).  
Likewise for γIFN, the stronger the TSBAB activity, the higher the fold rise for γIFN 
(Figure 32). 
 

































eye2 = 2.51 + -0.01 * pctsbab
R-Square = 0.33
 
Figure 31.   Correlation between IL2 and TSBAB in orbit of Balb/c. 
 
IL2 correlated with TSBAB (p<0.05).  The stronger the TSBAB, the 





were calculated as 



























































eyeg = 3.63 + -0.02 * pctsbab
R-Square = 0.29
Linear Regression 
Figure 32.   Correlation between γ IFN and TSBAB in orbit of Balb/c. 
 
γ-IFN correlated with TSBAB (p<0.05).  The stronger the TSBAB, the higher 
the fold rise in γ-IFN.
P < 0.05, 
TSBAB cAmp 
production results 
were calculated as 
























3.2.   Correlation of Cytokines with TRAB Measurements in Swiss Outbred Mice 
 In the orbit of Swiss outbred mice, there is significant correlation between 


























































40.00 60.00 80.00 100.00
TBII (%)
eyeg = 2.44 + -0.02 * pctbii
R-Square = 0.45
 
Figure 33.   Correlation between γ IFN and TBII in orbit of Swiss 
outbred. 
 
γ-IFN correlated with TBII (p<0.05).  The stronger the TBII, the higher the 
fold rise in γ-IFN. 
Linear Regression 
P < 0.05 
R-Square = 0.45 
TBII results were 
calculated as 




 In thyroid of treated Swiss outbred mice, there is correlation, though the 
change did not reach statistical significance (p=0.05), between IL2 and TBII activity.  
The stronger the TBII activity (meaning the smaller the %), the higher the fold 





































P = 0.05 




(%) of control 
average. 
Figure 34.  Correlation between IL2 and TBII in thyroid of Swiss mice 
 





















 In the spleen of Swiss outbred mice, there is significant correlation (p<0.05) 
between IL5 and FACS.  The correlation is and inverse correlation, where stronger 
the FACS signal, the lower the fold change in IL5 (Figure 35).  However, if only 










































P < 0.05 
R-square = 0.56 
Figure 35.   Correlation between IL5 and FACS in spleen of Swiss outbred. 
 
IL5 correlated inversely with FACS (p<0.05).  The stronger the FACS signal, the 



























































R-square = 0.82 
Figure 36.  Correlation between IL5 and FACS in spleen of Swiss outbred. 
 





















 There is also correlation between IL5 and TSBAB in the spleen of Swiss 
outbred mice.  The stronger the TSBAB activity, the larger the fold rise in IL5 with a 
p value of <0.05. 
 




































R-square = 0.41 
Figure 37.  Correlation between IL5 and TSBAB in spleen of Swiss mice. 
 
IL5 is correlated with TSBAB (p<0.05).  The stronger the TSBAB, the larger 
the fold rise in IL5 
TSBAB cAmp 
production results 
were calculated as 


















 The ratio of Th2 cytokines to Th1 cytokines in spleen, thyroid and orbit of 
Balb/c and Swiss outbred as is shown in table 22.  There were significant differences 
between the two strains of mice in Th2 to Th1 ratio.  They are indicated in the last 
column of table 22.  Differences were observed between the two strains with respect 
to IL5:IL2, IL4:γIFN in the spleen; IL5:γIFN and IL5:IL2 in the thyroid and 
IL5:γIFN, IL5:IL2 and IL4:IL2 in the orbit. 
 
Tissue Th2:Th1 Balb/c Median 
Swiss outbred 
Median 
Significant difference, P 
(comparison of 2 strains) 
IL5: γIFN 0.027 (0.019-0.034) 
0.022 
(0.019-0.032) Not Significant 
IL5:IL2 0.029 (0.024-0.041) 
0.083 
(0.052-0.104) <0.005 




IL4:γIFN 1.52 (1.15-2.43) 
0.97 
(0.69-1.21) <0.005 
IL5: γIFN 0.22 (0.11-0.53) 
89.39 
(22.4-283.61) <0.005 
IL5:IL2 0.10 (0.05-0.40) 
219.70 
(25.89-792.26) <0.005 
IL4:IL2 1.35 (0.61-3.24) 
3.25 
(0.70-5.07) Not Significant 
Thyroid 
IL4:γIFN 2.31 (0.90-3.83) 
1.57 
(1.06-2.40) Not Significant 
IL5: γIFN 15.90 (5.97-23.12) 
6.14 
(4.50-10.02) <0.05 
IL5:IL2 9.02 (6.40-19.07) 
3.22 
(1.68-5.30) <0.005 




IL4:γIFN 0.43 (0.23-0.71) 
0.48 
(0.16-0.92) Not Significant 
 
Table 22.   Relative fold change of Th2 cytokines to Th1 cytokines in mice 
injected with TSHR plasmids. 
 
Interquartile range in parentheses. 
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4.   Summary of Findings 
 
4.1.   Changes after Genetic Immunization 
 There was no significant change in total T4 levels between mice injected with 
receptor or empty plasmids in the outbred and inbred mouse strains.  Swiss outbred 
mice however put on more weight upon completion of protocol and this arose 
independent of T4 changes.  The described method of immunization produced 
significantly higher numbers of mice positive for FACS and TBII assays in Swiss 
outbred compared to Balb/c (Table 12 and 13).  The titers of these 2 assays were also 
significantly higher in outbred than in inbred mice.  The numbers of animals positive 
for TSAB or TSBAB in the 2 mouse strains were similar although the absolute 
TSBAB level in Swiss outbred mice injected with receptor were significantly stronger 
than those receiving empty plasmids (Table 14 and 15). 
 
4.2.   Th1 and Th2 Cytokine Expression 
 The cytokine profiles in mouse models of GD were studied and differences in 
cytokine gene expression in various tissues between Balb/c and Swiss outbred mice 
were demonstrated.  Table 23 summarizes these findings. 
1. In the spleen,  
• Balb/c mice injected with human TSHR have γIFN, IL2, IL4 and IL5 
expression levels comparable to that found in controls.  In Swiss outbred 
mice, expression of IL5 (Th2) was found to be significantly higher than 
that in controls (p<0.05).  Across strains of treated mice, the fold increase 
of IL5 in Swiss outbred and the fold drop in IL4 in Balb/c was statistically 
significant (Table 21, †). 
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• Within each individual Balb/c or Swiss outbred mouse injected with 
human TSHR, expression of IL5 (Th2) was much lower relative to Th1 
cytokines γIFN and IL2.  In contrast, expression of IL4 (Th2) was higher 
relative to these Th1 cytokines (Table 22). 
• In Balb/c mice, the higher the intensity of antibody production as 
measured by TSBAB, the higher the γIFN (Th1) expression (Figure 29).  
This is in contrast to IL2 (Th1), which declined with intensity of TBII 
(Figure 30).  In Swiss outbred mice, the higher the intensity of antibody 
production as measured by TSBAB, the higher the IL5 (Th2) expression 
(Figure 37).  This is in contrast to the relationship of IL5 to FACS, which 
was inverse; i.e. the higher the FACS, the lower the IL5 (Figure 35 and 
36).  It would appear that the expression of various cytokines correlated 
differently with different measurements of TRAB production. 
2. In the thyroid, 
• Balb/c mice injected with human TSHR have expression of Th1 cytokine 
γIFN was higher in compared to controls (p<0.005) (Table 21, **).  This 
rise of γIFN in Balb/c was significantly higher than in Swiss outbred mice 
(Table 21,†).  In contrast, the expression of Th2 cytokine IL5 was higher 
in Swiss outbred mice injected with human TSHR than controls (p<0.05) 
(Table 21, **).  The drop in IL2 in Swiss outbred is significant compared 
to the change in Balb/c mice (Table 21,†). 
• Within each individual Balb/c mouse injected with human TSHR, 
expressions of IL5 (Th2) to γIFN or IL2 (Th1) cytokines were consistently 
lower (Table 22).  In contrast, in Swiss outbred mice injected with the 
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receptor, expression of IL5 (Th2) was markedly enhanced compared to 
either γIFN or IL2 (Th1).  These differences between the 2 mouse strains 
were statistically significant (Table 22). 
• Although there was a trend for increasing TBII response to increasing 
level of IL2 in Swiss outbred mice, this did not reach statistical 
significance (Figure 34).  The rest of the TRAB measurement did not 
correlate with the cytokine expression. 
3. In the orbit,  
• Balb/c mice injected with TSHR, have significantly lower expression of 
IL5 than those exposed to empty plasmid (p<0.05) (Table 21, **).  
Expressions of γIFN (Th1) and expressions of IL4 and IL5 (Th2) were 
also all significantly lower in Swiss outbred mice injected with the 
receptor compared to the controls (p<0.05) (Table 21, **).  The lowering 
of IL4 and γIFN were significant compared to the changes seen in Balb/c 
mice (Table 21. †). 
• Within each individual Balb/c or Swiss outbred mouse injected with 
human TSHR, the expression of IL5 (Th2) relative to the Th1 cytokines 
(IL2 and γIFN) were higher whilst that of IL4 (Th2) relative to IL2 or 
γIFN were lower (Table 22). 
• In Balb/c mice, the higher the TSBAB production, the higher the rise in 
IL2 and γIFN (Th1) (Figure 31 and 32).  In Swiss outbred mice, γIFN 















V.   DISCUSSION 
 
1.   Technical Difficulties 
 
 During the course of this study, a few technical difficulties were encountered. 
• Sera samples taken from tail vein of mice at the start of the protocol posed a few 
challenges.  First of all, collecting blood from tail vein was time consuming.  
With each passing minute of blood collection from the tail vein, the body 
temperature of the mouse being bled decreased, causing the tail vein to constrict, 
therefore, even less blood could be collected before the flow stopped altogether.  
Secondly, drops of blood that were collected using capillary tubes would often 
clot if the blood flow was slow.  Thirdly, sera collected were often lysed due to its 
contact with skin on the tail.  This might have affected the biochemical results 
which relied on color for measurement.  Collection of sera at sacrifice by cardiac 
puncture though less time consuming and simpler, still run the same risk of being 
lysed when the syringe that was used for collection went right through the heart as 
happened with a few sera sample. 
• Due to the small volume of blood allowed for collection without killing the mice 
at the start of the protocol, sera sample obtained were often limited (<60 µl).  
Therefore, the volume used for biochemical and immunological marker testing 
were kept at the smallest volume allowed without compromising the accuracy of 
the tests.  There was no room for mistakes for because for some samples, there 
weren’t enough sera for experimental repetition for certain samples. 
• RNA extraction protocol was long and tedious due to the small specimen size.  
Much care had to be taken when separating the aqueous layer which contained the 
 66
RNA, from the interphase and organic layer which contained DNA and protein in 
order to obtain a DNA free RNA preparation.   Due to the small specimen size, 
especially for the thyroid specimens, RNA yield was also low.  When RNA yield 
is low, cDNA used for Real-Time PCR was low in concentration causing the 
expression of cytokines of interest to be undetectable.  These were the case in 1 
orbit sample and 2 thyroid samples in Swiss outbred and Balb/c strain 
respectively.  
• Real-Time PCR for cytokines generated unexpectedly low expression.  The 
probes and primers used initially were not sensitive and specific enough an 
accurate reading.  There were inconsistencies even within the triplicate sample.  
When the expression of a gene is very low, coupled with non ideal primers and 
probes, the difference of one copy of gene of interest can be translated into a Ct 
value change of 2 – 3, therefore, generating inconsistent results within the same 
sample.  After wasting much time and money trying to overcome these problems, 
new sets of primers and probes from Applied Biosystems, (TaqMan® Gene 
Expression Assays), which were tested and proven sensitive and specific were 
used in replace of the inferior primers and probes.  The machine used for 
amplification was also switched to accommodate the new primer and probe sets. 
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2.  Discussion of results 
 
2.1. Genetic Immunization in Balb/c versus Swiss Outbred mice 
 Genetic immunization appeared to work better in Swiss outbred than Balb/c 
mice.  It produced more FACS- and TBII- positive outbred mice.  It also generated 
stronger TSBAB levels which correlated significantly with specific cytokine in 
specified tissue compartment.  Specifically, it had a linear relationship with the 
expression of Th1 cytokines i.e. γIFN in the spleens & orbits and IL2 in the orbits of 
Balb/c mice.  In Swiss outbred, TSBAB had a linear relationship with the expression 
of Th2 cytokine IL5 of the spleens.  Therefore, TSBAB appeared to be a surrogate 
marker for Th1 cytokine in Balb/c and Th2 cytokine in outbred mice. 
 Amongst the cytokines, γIFN was more abundant in the thyroid in treated 
Balb/c mice (Table 21, **) whereas IL5 was more abundant in the thyroid and spleen 
of treated Swiss outbred mice (Table 21, **).  Striking differences were also present 
amongst the 2 mouse strains in the IL5: γIFN and IL5: IL2 ratios within the thyroid, 
where the ratios in Balb/c indicated a γIFN and IL2 dominance, whereas the ratios in 
Swiss outbred showed a IL5 dominance (Table 22).  Thus there appeared to be a bias 
towards a Th1 response in Balb/c and Th2 response in Swiss outbred in thyroid and 
spleen.  The exception is in the orbit where in both mouse strains, IL5 expression was 
lower compared with controls (Table 21).  In Swiss outbred, other cytokine such as 
IL4 and γIFN were also reduced in TSHR injected mice in comparison with controls 
(Table 21).  Thus in orbits of Swiss outbred mice, both Th1 and Th2 cytokines were 
down regulated where as in inbred Balb/c only IL5 was affected.  
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2.1.1. Genetic Immunization findings in Balb/c Mice 
 Genetic immunization was also efficient in generating mAbs against the 
TSHR.  Genetic immunization with TSHR cDNA in Balb/c mice was first described 
in 1998 by Costagliola et al [34].  Signs of thyroiditis were observed in the 14 
immunized Balb/c mice.  Clusters of immune cells were found at the periphery of the 
thyroid and they comprised CD4+ T cells and B cells.  With a single exception, 19 of 
the 20 mice immunized with the expression cDNA construct developed anti-TSHR 
antibodies.  Most of these antisera recognized both a recombinant fusion protein made 
in E. coli and the native TSHR expressed at the surface of CHO cells.  Most of the 
antisera presented a TBII or TSBAB activity, and one serum exhibited a clear and 
specific TSAB activity although this mouse had normal T4 level.  Whereas TBII and 
TSBAB activities can be easily obtained by immunization against recombinant 
immunogens, TSAB activity had been hard to obtain with earlier protocols.  In 
contrast, similar technique done in Balb/c mice produced very different results in the 
hands of another group of researchers.  Pichurin P et. al. reported absence of 
lymphocytic infiltration in the thyroids regardless of whether the mice did or did not 
have TRAB [40].  TRAB were undetectable in all DNA vaccinated Balb/c although in 
some animals, low levels can be found by flow cytometry.  The most recent 
publication on this subject by Baker G et al showed that genetic immunization was 
able to elicit TSAB and TBII response despite absence of histological evidence of 
thyroiditis [41].  Therefore, antibody responses towards a specific method of 
vaccination can vary despite experimentation in the same mouse strain depending on 
research groups.  The findings in the cohort of Balb/c mice were closer to the results 
reported by Pichurin P et al in that only 1 out of 14 mice were FACS positive and 3 
out of 14 were TBII positive and their titers were low.  However, generation of 
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TRAB with functional characteristics was more successful compared to the groups of 
Pichurin and Costagliola because there were 5 mice positive for TSAB and 5 mice 
positive for TSBAB. 
 One can only speculate about the basis for these differences.  The same mouse 
strain and the same immunization protocol were used.  Cardiotoxin, the agent found 
by Costagliola et al. to provide the strongest enhancement of genetic immunization 
was also given.  One factor could be the differing origins of the mice.  The animals 
were derived from different breeding colonies, Charles River in the study by 
Costagliola et al., Jackson Laboratory in the study by Pichurin et al and in our case 
Animal Holding Unit (AHU), MD1, National University of Singapore.  Thus 
differences in breeding protocols, environmental factors and housing conditions may 
affect results.  Facilities used by a number of researchers (apparently including that 
used by Costagliola et al.) are not pathogen-free.  Those used by Pichurin et al and the 
local animal facilities used in my study are in contrast pathogen-free.  Ironically, this 
may be less suited for the development of an animal model resembling Graves’ 
disease in humans.  Infections have been known to play a part in the pathogenesis of 
autoimmune thyroid disease.  It is possible therefore, that infections could contribute 
to the expression of experimentally induced Graves’ disease.  Strong evidence for 
environmental influences on immunological response also came recently from a 
report by Baker G et al where in a transfer model, antigen-induced secretion of IL4 
from splenocytes of recipient animals varied between the Cardiff and Brussel animal 
holding facilities despite the using the same primed splenocytes or lymphocytes.  
 In the study by Pichuria et al, low or undetectable levels of TSHR antibody in 
DNA vaccinated mice did not preclude the possibility of lymphocyte sensitization to 
the TSHR [40].  Indeed, splenocytes from TSHR-DNA vaccinated mice proliferated 
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and produced large amounts of γIFN in response to challenge with purified TSHR-
289, an ectodomain variant corresponding to the TSHR A-subunit [40].  Splenocyte 
proliferation and γIFN production were unrelated to TSHR antibodies in the donor 
mouse’s serum.  In addition, the genetic immunization study by Costagliola et al 
produced 3 monoclonal antibodies of IgG2a-κ isotype [34].  The IgG2a- κ isotype 
reflects a switch to Th1, probably as a consequence of γIFN production.  The findings 
in my study were corroborated by the above mentioned data.  γIFN was found to be 
more abundant in the thyroids of TSHR vaccinated Balb/c mice than those of 
controls.  There was a dominance of γIFN and IL2 to IL5 in the ratio calculation of 
the thyroidal cytokines.  TSBAB also had a linear relationship with the expression of 
Th1 cytokines i.e. γIFN in the spleens & orbits and IL2 in the orbits of Balb/c mice. 
 Finding of γIFN production in TSHR-vaccinated Balb/c mice is unusual 
because this strain of mouse typically shows a bias toward Th2 responses, at least 
with respect to Leishmania infection [42].  Moreover, it was previously shown by 
Many et al (a collaborator of Costagliola) that TSHR-primed T cells generated by 
DNA vaccination and transferred to naive Balb/c recipients induced thyroiditis 
characterized by a Th2 type response, with cells containing IL-4 and IL-10 [33].  Yet, 
my current data is consistent with numerous other observations that DNA vaccination 
against diverse antigens induces Th1-type responses as reflected in γIFN production 
and antibodies of subclass IgG2a [43-45]. 
 
2.1.2. Genetic Immunization findings in Swiss Outbred Mice 
 Genetic immunization of outbred NMRI mice was also first reported by 
Costagliola et al [32] in which all animals had antibodies detected by flow cytometry 
and 1 out of 5 female outbred mice developed T4 elevation with circulating TSAB 
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accompanied by thyroid hyperplasia.  Their glands displayed a lymphocytic 
infiltration characteristic of a Th2 reaction with IL4 producing T cells and B cells.  A 
great majority (~75%) developed blocking TSBAB.  The TRAB profiles found in my 
cohort of experimental Swiss outbred mice were similar with regards to flow 
cytometry (8 positive out of 10) and TBII (9 positive out of 10).  Development of 
TSAB was also detected in 2 mice out of cohort of 10 animals although only one of 
the 2 had elevated total T4 level.  TSBAB was only found in 50% of the animals.  
Expression of Th2 cytokine IL5 was higher in Swiss outbred mice injected with 
TSHR compared to controls in the splenic and thyroidal tissues.  There was also a 
drop in expression of IL2 (Th1) cytokine in the vaccinated thyroid relative to control, 
which differ significantly from that in Balb/c mice.  There was also a large 
dominance of IL5 to IL2 or γIFN expression in the ratio calculation and this contrast 
sharply with the findings in Balb/c mice.  Thus Swiss outbred mice tended towards a 
Th2 bias upon genetic immunization with the human TSHR.  Correlation of cytokines 
with various TRAB measurements tended to be heterogeneous with no consistent 
direction of change.  Finding of Th2 response is not surprising since due to the role of 
autoantibodies, Graves’ disease has long been considered to be a Th2-dominated 
disease.  Support for this hypothesis includes features of atopy such as elevated serum 
IgE in some Graves’ patients [46] as well as the induction of Graves’ disease in 
patients with multiple sclerosis (a Th1-dominated autoimmune disease) following 
treatment with monoclonal anti-CD52 antibody [47].  On the other hand, cytokine 
expression profiles in sera and thyroid tissues from Graves’ patients indicate a mixed 
Th1/Th2 immune response [48].  Moreover, Graves’ disease generally ameliorates 
during pregnancy, a Th2-dominant state [49].  Even more important, TSAB are IgG1 
[13] a Th1-type subclass in humans. 
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 A model of GO had been described by transfer of TSHR-primed T cells to 
naive syngeneic recipients where priming was achieved by genetic immunization (GI) 
with a plasmid encoding the human TSHR.  Th2 thyroiditis developed in ~ 60% of 
the recipients, about one third of these animal with thyroiditis also displayed orbital 
changes, including immune infiltration and edema, similar to those seen in GO [33].  
The severity of the orbital changes correlated positively with the extent of the Th2 
skew in the thyroid immune infiltrate of that animal.  GO changes can also be 
observed by genetic immunization of NMRI outbred mice.  Orbital changes include 
extraocular muscles dissected by edema and a fibrotic amorphous material 
accompanied by macrophages and mast cells in approximately 20% of the animals 
[32].  However, ocular muscle anatomy is complex and easily disturbed if muscle 
contraction occurs before fixation.  Recent work by Baker et al suggested that 
histological GO findings described by Many et al and Costagliola et al mentioned 
above could be muscle contraction and inadequate fixation artifacts [41].  The authors 
were unconvinced that these 2 murine models constitute good GO model due to lack 
of macroscopic changes of proptosis and muscle hypertrophy.  Due to small sample 
material, both orbital contents were subjected to RNA extraction and thus histology 
of this tissue compartment was not examined.  Certainly in comparison with the 
control mice which were injected with empty plasmid, there was down regulation of 
IL5 expression in both mouse strains exposed to the TSHR and down regulation of 
IL4 and γIFN in TSHR immunized outbred mice.  This would imply a relatively 
quiescent immunological environment within the orbital compartment.  Nevertheless 
despite lack of rise in expression, TRAB measurements in terms of TSBAB and TBII 
titers were still correlated positively with the fold change in IL2 and γIFN in Balb/c 
mice and γIFN in outbred mice respectively. 
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 2.2. Significance of findings in Balb/c and Swiss outbred mice 
 Swiss outbred mice provided a more heterogeneous genetic background, 
which made them less resistant to a TSAb response.  A TSAb response in mice might 
be incompatible with the genetic background of the inbred Balb/c strain.  There is 
evidence in humans that GD is a multigenic/multifactorial disease [50] and that 
genetic background is a major determinant of the ability to generate TSAbs.  
Moreover, a heterogeneous genetic makeup bears closer resemblance to human 
disease. Thus, Swiss outbred mouse is felt to be more suitable strain in generating 
such a GD or GO model.  Balb/c model of GD may not be useful for the study of GO.  
However, it remains a useful tool for generation of antibodies recognizing the native 
structure of the human TSHR, with uses including the generation of mouse 
monoclonal TSHR antibodies and future TSHR studies [51].  
 
2.3. Mouse GO versus Human GO 
 Bilateral orbital contents were utilized for RNA extraction leaving no room 
for histological examination of eye for verification of inflammatory changes.  Neither 
could other imaging techniques such as computed tomography or magnetic resonance 
scanning be employed in this mouse study.  Therefore it was not possible in this study 
to determine if histological or radiological characteristics of GO were present in the 
vaccinated mice. In addition, only histological resemblance between human GO and 
mouse GO were described in previous studies. No gross phenotypic description, in 
the lid or globe, was ever reported in mouse GO.  Furthermore, mice and humans 
possess differences in the structures of their skeletal orbits which could contribute 
variations in response to eye inflammation. For example, physical characteristics such 
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as intra-ocular pressure, thought to play a role in pathogenesis of GO, is expected to 
vary in the 2 mammalian systems. 
 
2.4. Clinical relevance of differences in cytokine profile in Mouse Model 
 Cytokines are produced in the thyroid and the orbit of patients with 
autoimmune thyroid diseases such as GD. This results in a continuation inflammatory 
reaction, which can directly affect thyroid function.  In the outbred mice, the cytokine 
profile of thyroid was reported to be predominantly Th2 type with IL5 dominance 
[32].  These mice were TSAb positive, hyperthyroid, showed thyroid; all 
characteristic features of human GD.  In the inbred mice [34], the cytokine profile 
present in the thyroid was Th1 with gamma interferon as the predominantly secreted 
cytokine.  These mice produced mainly TSBAb and developed thyroiditis, a 
destructive inflammation of the thyroid gland.  The findings in inbred mice mimicked 
human Hashimoto’s thyroiditis. Parallels could be drawn from a study in human 
subjects by Heuer et al [52]. In humans, a Th1 response was demonstrated in 
Hashimoto’s thyroiditis while a Th2 response was seen in thyroid of GD. 
 
2.5. Limitation of current study 
 The mouse model of GO that was generated by Costagliola group [32] was 
adopted primarily because this remains the only reliable model in which histological 
features of GO could be reproduced associated with inflammatory infiltrates. 
However the minute amount of tissue samples from the orbit and thyroid proved the 
limiting factor in this study. We were only able to look into changes in cytokine 
expression by real time PCR method.  Histology of thyroid and the eye were not 
done.  Instead, TSHR antibody production was utilized as serological surrogate to 
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indicate presence of successful immunization.  This problem could well be overcome 
by using bigger animals such as rats, rabbits or hamsters for experimentation. 
However, their immune response to a human TSHR may not be identical.  
 
2.6. Possible Future Work / Experiments 
 Future work using macaques may offer additional benefits: 1) the structure of 
bony orbit in a macaque is similar to a human’s, 2) the size of the sample makes 
available enough tissue for RNA collection as well as histology study, and 3) 
computed tomography and magnetic resonance imaging can potentially be done on 
these larger animals.  However one potential shortfall in the primate model may be 
the close sequence homology between human and macaque TSHR, which could pose 
difficulty in inciting immunological response.  Possible solutions include the use of 
methylated DNA for vaccination and usage of adjuvant. Once these problems are 
overcome, the primate model could be use to study factors affecting the pathogenesis 
of GO and testing out new immunomodulatory therapies which could revolutionize 
the treatment and prognosis in this disease. 
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VI.   CONCLUSION 
 
 In conclusion, the verdict on the paradigm of Th1/Th2 response in GD and in 
particular, GO, is still out.  Th1/Th2-type responses analyzed using two murine 
strains by the same method of immunization using the same plasmid prepared in 
identical ways, housed in the same animal holding area with no seasonal variation, 
fed with the same water and chow with the same iodine content provide conflicting 
observations.  TRAB measurements by various modalities varied and the types of 
cytokine expression also differed.  The only variance in this study is in the genetic 
makeup of outbred and inbred mice.  It is possible that the genetic diversity in outbred 
mice contribute to a more plausible model for human GD. 
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